Notice for doxecitine and doxribtimine (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Active ingredients
doxecitine and doxribtimine
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
powder for oral solution
Indication
Treatment of thymidine kinase 2 deficiency (TK2d) in adults and paediatric patients
Therapeutic area
Inherited metabolic disorders